PRNP P102L

What is the clinical picture?

GSS, anchored in cerebellar degeneration. Presentation is typically progressive gait ataxia, with dysarthria, lower limb weakness, reduced or absent tendon reflexes and paraesthesiae, and cognitive decline following rather than leading. Reviews describe GSS presentations as falling into early cerebellar, parkinsonian or frontotemporal dementia-like patterns, with periodic sharp wave complexes on EEG and CSF 14-3-3 usually not detected.

The 2017 review names P102L as the most commonly reported GSS mutation, with literature onset ranging from 27 to 66 years and durations from 7 to 132 months. In the UCSF centre’s own P102L patients, onset was 44 years with a standard deviation of 12 and a range of 24 to 57, and duration 44 months with a standard deviation of 13 and a range of 28 to 60.

A duration range from 7 months to 11 years in the same variant is the figure worth carrying into a consultation. It means that neither a rapid decline nor an illness lasting a decade is inconsistent with P102L, and that prognostic statements to a family should be given as a range with the uncertainty attached.

What is known about penetrance?

P102L is among the most penetrant PRNP variants. The 2016 population-control analysis, comparing 16,025 prion disease cases with 60,706 ExAC exomes and 531,575 genotyped individuals and estimating lifetime risk from case against control allele frequencies with a baseline of roughly 1 in 5,000, found allele frequencies for E200K, D178N, P102L and A117V consistent with up to 100 percent penetrance. A 2022 review describes D178N and P102L as nearly completely penetrant.

Two qualifications belong with that. The 2016 estimate is an upper bound compatible with the data, with confidence intervals the authors described as spanning more than an order of magnitude. And high penetrance says nothing about timing: with reported onset spanning four decades, a carrier cannot be given an age.

How does the diagnosis get made, and what can go wrong?

In a symptomatic patient: the clinical syndrome, a three-generation family history, MRI, CSF studies and PRNP sequencing, with the gene test confirming.

The failure mode is specific to the tempo. A slowly progressive ataxia in a patient in their forties, with a normal EEG and negative CSF 14-3-3, looks like a hereditary ataxia or a spinocerebellar degeneration, and in families where the diagnosis has never been made the prion question may not be raised for years. Where a family history of ataxia and dementia exists, PRNP belongs in the differential alongside the ataxia genes.

The seeding assay result then depends on the laboratory. In the 2026 Canadian comparison of 116 diagnostic CSF samples, the 10 P102L cases gave 10 of 10 positive with a modified end-point assay using a deer mouse recombinant substrate, 8 of 10 with the standard hamster end-point assay, and 4 of 10 with second-generation IQ-CSF RT-QuIC. Across all twelve GSS cases in that panel, 9 of 12 by the hamster assay became 12 of 12 with the modified substrate, while overall sensitivity rose from 87.1 percent and 72.4 percent to 96.6 percent. The paper describes the hamster end-point assay as the accredited Canadian CSF test since 2016.

An earlier series of 56 CSF samples from genetic prion disease reported 78 percent sensitivity for P102L against 87 percent for E200K and 100 percent for D178N; that figure comes from a listing in which the assay generation was not stated, so the ordering is more reliable than the number.

So a negative CSF seeding result in a suspected P102L case means different things in different laboratories, and the substrate should be recorded alongside the result. Where the family variant is known, telling the laboratory lets the result be interpreted properly. How prion disease is diagnosed covers the panel and rapidly progressive dementia and CJD: more detail the assay comparison.

What does the long course mean for care?

It changes the shape of it. An illness over several years is managed as a progressive neurological disability: physiotherapy for gait and falls, speech and language therapy for dysarthria and later dysphagia, orthotics and home adaptation, and symptom control for spasticity, pain, sleep and mood.

Early palliative involvement remains appropriate and is recommended in prion disease generally; in a multi-year illness it means intermittent involvement over years rather than terminal care. Gerstmann-Straussler-Scheinker disease: more detail and how prion disease progresses: more detail cover the management.

Benefits, income protection and work questions also arrive differently from a four-month illness, and are worth raising early rather than at crisis.

What should counselling cover for this variant?

The usual framework applies: counselling before testing, time between sessions, results in person, testing not offered under 18, and declining as a recognised choice. Genetic counselling comes first and predictive testing: more detail set that out.

Three points are P102L-specific. The wide onset range means that a relative who has passed the age at which their parent became ill has not thereby been reassured. The wide duration range means that one family member’s course does not predict another’s. And because onset can fall in the 20s and 30s, reproductive questions often arise before anyone has considered predictive testing; family planning options sets out the published routes, including those that do not require a prospective parent to learn their own status.

Where next?

PRNP variants is the overview, A117V the other common GSS variant, octapeptide repeat insertions the group that also produces GSS-like illness, and P102L for researchers the scientific page.

This page summarises published literature and is not clinical or genetic advice. No figure here describes the position of any particular person or family.